Drug Trial Radar · NCT04786795
MITE in the Treatment of Dyspepsia After Cholecystectomy
Last checked: Nov 19, 2026Latest source record: Mar 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
990
Planned (sponsor's estimate)
Start
Mar 1, 2021
Primary completion
Feb 1, 2022
Study completion Feb 2022
Sponsor
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To confirm the clinical efficacy of Compound Azintamide Enteric-coated Tablets in the treatment of patients with dyspepsia after cholecystectomy (such as abdominal distension, abdominal pain/abdominal discomfort, diarrhea/fatty stool, early satiety, belching, loss of appetite, etc.) by comparing with positive control drug, to observe its safety, and to evaluate the quality of life of subjects before and after treatment
Conditions
- Patients With Dyspeptic Symptoms After Cholecystectomy
Interventions
Compound Azintamide Enteric-coated TabletsDrug
the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid TabletsDrug
the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Symptom assessmentTime frame: 28days
- Efficacy evaluationTime frame: 28days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.